Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 14 de 14
Filtrar
Más filtros

Bases de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Medicina (Kaunas) ; 58(1)2022 Jan 14.
Artículo en Inglés | MEDLINE | ID: mdl-35056433

RESUMEN

Background and Objectives: Complementary and alternative medicines (CAMs) are generally considered non-scientific and poor effective therapies. Nevertheless, CAMs are extensively used in common clinical practice in Western countries. We decided to promote a Delphi consensus to intercept the opinion of Italian physicians on CAM use in clinical practice. Materials and Methods: We run a Delphi-based consensus, interviewing anonymously 97 physicians. Of these, only 78 participate to the questionnaire. Results: Consensus about agreement and disagreement have been reached in several topics, including indication, as well as safety issues concerning CAMs. Conclusions: The use of CAMs in clinical practice still lacks evidence. Experts agree about the possibility to safely use CAMs in combination with conventional medicines to treat non-critical medical conditions.


Asunto(s)
Terapias Complementarias , Médicos , Humanos , Encuestas y Cuestionarios
2.
Biomolecules ; 11(3)2021 02 26.
Artículo en Inglés | MEDLINE | ID: mdl-33652804

RESUMEN

In recent years, the interest in oxygen-ozone (O2O3) therapy application has considerably increased in the field of rehabilitation. Despite its widespread use in common clinical practice, the biochemical effects of O2O3 are still far from being understood, although its chemical properties seem to play a pivotal role in exerting its positive effects on different pathological conditions. Indeed, the effectiveness of O2O3 therapy might be partly due to the moderate oxidative stress produced by O3 interactions with biological components. O2O3 therapy is widely used as an adjuvant therapeutic option in several pathological conditions characterized by chronic inflammatory processes and immune over-activation, and most musculoskeletal disorders share these pathophysiological processes. The present comprehensive review depicts the state-of-the-art on the mechanisms of action, safety and effectiveness of O2O3 therapy in the complex scenario of the management of musculoskeletal disorders. Taken together, our findings suggest that O2O3 therapy seems to reduce pain and improve functioning in patients affected by low back pain and knee osteoarthritis, as reported by several studies in the literature. However, to date, further studies are warranted to clearly investigate the therapeutic effects of this promising therapy on other musculoskeletal disorders in the field of rehabilitation.


Asunto(s)
Enfermedades Musculoesqueléticas/tratamiento farmacológico , Enfermedades Musculoesqueléticas/metabolismo , Osteoartritis de la Rodilla/tratamiento farmacológico , Osteoartritis de la Rodilla/metabolismo , Oxígeno/uso terapéutico , Ozono/uso terapéutico , Animales , Fibromialgia/tratamiento farmacológico , Fibromialgia/metabolismo , Humanos , Dolor de la Región Lumbar/tratamiento farmacológico , Dolor de la Región Lumbar/metabolismo , Dolor de Cuello/tratamiento farmacológico , Dolor de Cuello/metabolismo
3.
Clin Interv Aging ; 15: 1077-1084, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32753859

RESUMEN

OBJECTIVE: To assess physical performance, number of falls, previous fragility fractures, and ongoing pharmacological therapy in a cohort of post-menopausal women, according to their risk of falling. METHODS: In this multicenter cross-sectional study, we recruited in a 3-year period (May 2016 to April 2019), women aged >60 years referred to seven Osteoporosis and Bone Metabolism Outpatient Services of the Italian Group for the Study of Metabolic Bone Diseases. The study population was divided into three groups according to the risk of falling, assessed through the Elderly Fall Screening Test (EFST): low risk (EFST score=0-1); moderate risk (EFST=2-3); high risk (EFST=4-5). Outcome measures were: 4-meter gait speed (4MGS); unipedal stance time (UST); number of falls in the previous year; previous fragility fractures; ongoing pharmacological therapy. RESULTS: We analyzed 753 women (mean aged 70.1±9.2 years): 378 (50.2%) at low risk of falling, 247 (32.8%) at moderate risk, and 128 (17.0%) at high risk. 4MGS and UST resulted as pathological in the 93.9% and 99.2%, respectively, of women at high risk. There were significant differences among groups for both outcomes (p<0.001). There was also a significant difference among groups (p<0.001) in terms of previous falls and fragility fractures. Lastly, there were significant differences (p<0.05) among groups in using antihypertensive drugs, antiplatelet agents, anticoagulants, antidepressants, anti-osteoporotic drugs, and vitamin D, and/or calcium supplementation. CONCLUSION: Physical performance, prevalence of falls and fragility fractures, and an assessment of pharmacological therapy should be investigated in post-menopausal women because of their significant correlation with risk of falling.


Asunto(s)
Accidentes por Caídas/estadística & datos numéricos , Osteoporosis/epidemiología , Posmenopausia , Velocidad al Caminar , Accidentes por Caídas/prevención & control , Anciano , Anciano de 80 o más Años , Estudios Transversales , Femenino , Fracturas Óseas/epidemiología , Humanos , Italia , Osteoporosis/tratamiento farmacológico , Factores de Riesgo , Vitamina D/uso terapéutico
4.
J Back Musculoskelet Rehabil ; 33(3): 347-354, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32144974

RESUMEN

BACKGROUND: There is little evidence on intra-articular (IA) treatment in knee osteoarthritis (KOA) and there is a lack of long-term follow-up studies. OBJECTIVE: To assess the long-term effectiveness and safety of IA oxygen-ozone (O2O3) and hyaluronic acid (HA) in terms of functioning in KOA patients over a 31-week period. METHODS: Patients aged ⩾ 60 years with KOA were randomly allocated to receive 4 IA knee injections (1/week) of O2O3 or HA (T0-T3) and a follow-up visit 4 weeks after the fourth injection (T4). In this extension study we assessed VAS and safety in patients with Visual Analogue Scale (VAS) ⩾ 4 at the at 6-month follow-up visit (T5), undergoing a second treatment cycle (T5-T8) and 1-month follow-up visit (T9). RESULTS: Forty-two patients (aged 70.5 ± 5.8 years) were randomly allocated to O2O3 (n= 22) or HA group (n= 20). Twenty-three underwent another IA cycle: 12 (54.6%) in the O2O3 group and 11 (55.0%) in the HA group. Both groups showed significant reduction in VAS (p< 0.013) compared to baseline during both cycles. At follow-up visits (T4 and T9), VAS was significantly lower in the HA group (p< 0.013). There were no differences in adverse events occurrence between groups. CONCLUSIONS: IA O2O3 might be comparable to HA in terms of effectiveness and safety in reducing pain in KOA patients, although at both follow-up visits (T4 and T9) VAS was significantly lower in the HA group.


Asunto(s)
Ácido Hialurónico/administración & dosificación , Osteoartritis de la Rodilla/terapia , Oxígeno/administración & dosificación , Ozono/administración & dosificación , Viscosuplementos/administración & dosificación , Anciano , Femenino , Humanos , Inyecciones Intraarticulares , Articulación de la Rodilla , Masculino , Dolor , Método Simple Ciego , Resultado del Tratamiento , Escala Visual Analógica
5.
Aging Clin Exp Res ; 32(5): 959-962, 2020 May.
Artículo en Inglés | MEDLINE | ID: mdl-31838642

RESUMEN

Hip fractures are the most common osteoporotic fractures related to disability in older adults, requiring surgery and a subsequent rehabilitation treatment. Sarcopenia is currently considered as a predictive of worse outcome in hip fracture patients and myostatin has been recently proposed a potential biomarker of this condition. Twenty hip fracture patients after total hip replacement (mean aged 75.9 ± 2.4 years) were randomly divided into two groups of ten subjects (groups A and B). Both groups performed a rehabilitation program (5 sessions of 40 min/week for 2 weeks, followed by home-based exercise protocol). Group A received also 2-month amino acid supplementation. Serum myostatin levels significantly decreased after 2 months in both group A (p = 0.01) and group B (p = 0.03) in sarcopenic patients only in group A (p = 0.04). These results suggest that myostatin might be considered a promising biomarker of sarcopenia in hip fracture older adults' patients undergoing rehabilitation and amino acid supplementation.


Asunto(s)
Fracturas de Cadera/rehabilitación , Miostatina/sangre , Anciano , Anciano de 80 o más Años , Artroplastia de Reemplazo de Cadera , Biomarcadores/sangre , Ejercicio Físico , Femenino , Fracturas de Cadera/cirugía , Humanos , Masculino , Monitoreo Fisiológico , Evaluación Nutricional , Fracturas Osteoporóticas , Datos Preliminares , Sarcopenia
6.
Ann Phys Rehabil Med ; 62(4): 214-219, 2019 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-31228593

RESUMEN

BACKGROUND: Botulinum toxin type A (BoNT-A) injection is an effective treatment for lower-limb spasticity and should be offered as first-line treatment for focal manifestations. Although its possible role has been hypothesized, the efficacy of electrical stimulation (ES) of antagonists of the injected muscles for improving clinical outcome after BoNT-A injection remains to be established. OBJECTIVES: This randomized single-blind pilot study aimed to investigate the efficacy of ES of antagonist muscles as adjunct treatment after BoNT-A injection to plantar flexor muscles in hemiplegic patients with spastic equinus foot. METHODS: After BoNT-A injection at triceps surae, patients were randomly allocated to 2 groups: group 1, single ES session on injected muscles plus 5 sessions of ES on antagonist muscles, and group 2, single ES session on injected muscles alone. Both groups underwent daily physical therapy for 60min for 2 weeks (5 days/week). Assessments were performed before treatment (T0) and at 10 days (T1), 20 days (T2), and 90 days (T3) after treatment. Our primary outcome was gait velocity at a comfortable speed at T2 (10-m walk test [10MWT]). The following were secondary outcomes: triceps surae spasticity (Modified Ashworth Scale), ankle passive range of motion (pROM), strength of tibialis anterior muscle, and 2-min walk test (2MWT). RESULTS: The 30 patients enrolled were randomly allocated to the 2 groups: 15 in group 1 and 15 in group 2. At T1, T2 and T3, both groups showed a significant reduction in muscle tone and an increase in ankle pROM (P<0.05). At T2 and T3, both groups showed a significant increase in 10MWT and 2MWT. The groups did not significantly differ in tibialis anterior strength or primary or secondary outcome measures. CONCLUSIONS: ES of antagonist muscles does not improve clinical outcomes in the post-stroke spastic equinus foot after BoNT-A injection.


Asunto(s)
Toxinas Botulínicas Tipo A/uso terapéutico , Terapia por Estimulación Eléctrica , Pie Equino/terapia , Espasticidad Muscular/terapia , Fármacos Neuromusculares/uso terapéutico , Anciano , Terapia Combinada , Pie Equino/tratamiento farmacológico , Pie Equino/etiología , Femenino , Hemiplejía/tratamiento farmacológico , Hemiplejía/etiología , Hemiplejía/terapia , Humanos , Pierna , Masculino , Persona de Mediana Edad , Espasticidad Muscular/tratamiento farmacológico , Espasticidad Muscular/etiología , Resistencia Física , Proyectos Piloto , Recuperación de la Función , Método Simple Ciego , Accidente Cerebrovascular , Rehabilitación de Accidente Cerebrovascular , Resultado del Tratamiento
7.
Ann Phys Rehabil Med ; 62(4): 291-296, 2019 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-30219307

RESUMEN

BACKGROUND AND OBJECTIVE: A wide range of adjunct therapies after botulinum toxin administration have been proposed. The aim of the present paper is to provide an overview of major writings dealing with adjuvant (non-pharmacological) treatments associated with botulinum toxin for managing spasticity in order to provide some up-to-date information about the usefulness of the most commonly used procedures. METHODS: The literature in PubMed was searched with the MeSH terms botulinum toxins, muscle spasticity, physical therapy modalities, and rehabilitation. The results were limited to studies focusing on adjuvant treatments associated with botulinum toxin for managing spasticity. We excluded papers on the use of non-drug treatments for spasticity not associated with botulinum toxin serotype A (BoNT-A) injection. Relevant literature known to the authors along with this complementary search represented the basis for this overview of the literature. RESULTS: Adhesive taping and casting effectively improved the botulinum toxin effect in patients with upper- and lower-limb spasticity. There is level 1 evidence that casting is better than taping for outcomes including spasticity, range of motion and gait. However, consensus about their most appropriate timing, duration, target and material is lacking. In terms of physical modalities combined with botulinum toxin injection, we found level 1 evidence that extracorporeal shock wave therapy is better than electrical stimulation for some post-injection outcomes including spasticity and pain. Furthermore, electrical stimulation of injected muscles might be useful to boost the toxin effect. However, the best stimulation protocol has not been defined. In addition, we found level 2b evidence that whole-body vibration therapy might reduce spasticity with cerebral palsy. CONCLUSION: Future research in this field should focus on investigating the most appropriate post-injection treatment protocol for each goal to achieve.


Asunto(s)
Toxinas Botulínicas Tipo A/uso terapéutico , Espasticidad Muscular/terapia , Fármacos Neuromusculares/uso terapéutico , Cinta Atlética , Moldes Quirúrgicos , Terapia Combinada , Terapia por Estimulación Eléctrica , Tratamiento con Ondas de Choque Extracorpóreas , Humanos , Inmovilización , Espasticidad Muscular/tratamiento farmacológico , Aparatos Ortopédicos , Ensayos Clínicos Controlados Aleatorios como Asunto , Férulas (Fijadores) , Vibración/uso terapéutico
8.
Aging Clin Exp Res ; 31(10): 1517-1524, 2019 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-30539540

RESUMEN

BACKGROUND: Physical exercise and nutrition seem to have a key role in the management of hip fracture patients. AIM: To evaluate the impact of a 2-month rehabilitative protocol combined with dietetic counseling, with or without essential amino acid supplementation, on functioning in hip fracture patients. METHODS: In this pilot randomized controlled study, we recruited patients aged more than 65 years, at 3 months after hip fracture. We randomly assigned the participants into two groups (A and B). Both groups performed a physical exercise rehabilitative programme (five sessions of 40 min/week for 2 weeks, followed by a home-based exercise protocol) and received a dietetic counseling; only group A was supplemented with two sachets of 4 g/day of essential amino acids (Aminotrofic®). We evaluated at baseline and after 2 months of intervention (T1): hand grip strength, Timed Up and Go, and Iowa Level of Assistance scale (ILOA). RESULTS: The 32 hip fracture patients (mean aged 79.03 ± 7.80 years) were allocated into two groups: group A (n = 16) and group B (n = 16). All the participants showed significant differences in all outcomes at T1 (p < 0.017). Sarcopenic patients in group A (n = 10) showed statistically significant differences in all the primary outcomes at T1 (p < 0.017), whereas sarcopenic patients in group B (n = 13) showed a significant reduction of ILOA only. In non-sarcopenic patients, we found no differences at T1 in all outcome measures. DISCUSSION: Hip fractures are a complex multifactorial condition of the elderly that determines devastating effects on functioning and independence. CONCLUSION: A multidisciplinary rehabilitative and nutritional intervention seems to be effective on functioning in hip fracture patients, in particular sarcopenic ones.


Asunto(s)
Aminoácidos Esenciales/uso terapéutico , Suplementos Dietéticos , Fracturas de Cadera/dietoterapia , Fracturas de Cadera/rehabilitación , Anciano , Anciano de 80 o más Años , Terapia por Ejercicio/métodos , Femenino , Fuerza de la Mano , Humanos , Masculino , Evaluación de Resultado en la Atención de Salud , Proyectos Piloto , Sarcopenia
9.
Med Lav ; 107(2): 112-28, 2016 Mar 24.
Artículo en Italiano | MEDLINE | ID: mdl-27015027

RESUMEN

BACKGROUND: In the last few years, the incidence of upper limbs tendon injuries has seen a dramatic increase among workers. Conservative treatment is the first choice to relieve symptoms, allowing a safe return to work. However, the scientific evidence of its  efficacy is widely debated. OBJECTIVE AND METHODS: Research and literature review on the efficacy of conservative treatment of upper limbs tendon injuries in occupational settings. RESULTS: A total of 271 references were found on Medline and Embase up to May 2015. 116 papers were excluded, 155 articles were included and the full text read. CONCLUSIONS: After a timely diagnosis, a prompt start of the rehabilitation programme and a limitation of complete rest are useful to relieve pain, increase functionality and reduce work absenteeism in the long term. Conservative treatment combinations, such as manual therapy, specific exercises focused on increasing flexibility and muscle strength and specific-gesture training, achieves more significant results than a single isolated treatments. Currently, there is no strong scientific evidence to support prolotherapy and Platelet-Rich Plasma (PRP). However, current promising results will encourage further studies. Awareness among both employers and employees about prevention and risk factors should be enhanced.


Asunto(s)
Enfermedades Profesionales/patología , Enfermedades Profesionales/terapia , Tendinopatía/patología , Tendinopatía/terapia , Extremidad Superior/patología , Terapia por Ejercicio , Humanos , Incidencia , Italia/epidemiología , Enfermedades Profesionales/complicaciones , Enfermedades Profesionales/epidemiología , Enfermedades Profesionales/rehabilitación , Aparatos Ortopédicos , Tendinopatía/epidemiología , Tendinopatía/etiología , Tendinopatía/rehabilitación , Resultado del Tratamiento
10.
J Arthroplasty ; 30(11): 2038-42, 2015 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-26072302

RESUMEN

Pain management is a main determinant of functional recovery after total knee arthroplasty (TKA). We performed a randomized, controlled, double blind study to evaluate additive efficacy of periarticular anesthesia in patients undergoing TKA in reducing post-operative pain, operated limb edema and improving post-operative mobility. Patients were randomly assigned to study or control group; all subjects received the same analgesic protocol; before wound closure, the study group received also a periarticular anesthesia (ropivacaine 1% 20 mL). The results show no statistical differences in any of the variable evaluated. Our data suggest that additive periarticular anesthetic protocol with ropivacaine 1% 20 mL is not superior to oral and intravenous analgesia alone in patients undergoing TKA, regarding post-operative pain control, operated limb edema reduction and post-operative mobility improvement.


Asunto(s)
Amidas/administración & dosificación , Anestesia Local/estadística & datos numéricos , Anestésicos Locales/administración & dosificación , Artroplastia de Reemplazo de Rodilla , Dolor Postoperatorio/prevención & control , Adulto , Anciano , Analgesia/métodos , Analgésicos/administración & dosificación , Anestesia , Anestesia Local/métodos , Método Doble Ciego , Edema/prevención & control , Femenino , Humanos , Masculino , Persona de Mediana Edad , Manejo del Dolor , Dimensión del Dolor , Estudios Prospectivos , Rango del Movimiento Articular , Ropivacaína
11.
Rheumatol Int ; 32(11): 3365-72, 2012 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-22045518

RESUMEN

Recent reports suggest a role of hypovitaminosis D in the pathogenesis of inflammatory autoimmune diseases (ARD); we investigated 25(OH)vitamin D plasma level before and after supplementation in ARD and NARD (non-ARD: osteoporosis and/or OA) patients. We retrospectively evaluated 572 consecutive clinical records of adult patients at immuno-rheumatology and rehabilitative units of our institution from January 2006 to October 2009. We excluded patients with vitamin D supplementation or renal failure, primary hyperparathyroidism, liver failure. We recorded 25(OH)vitamin D plasma concentration of 245 patients together with other clinical data. We then evaluated 25(OH)vitamin D plasma concentration of 100 (43 ARD and 57 NARD) patients previously included who underwent 750-1,000 UI/die 25(OH)vitamin D supplementation for at least 6 months. Appropriate statistical analysis was performed. The median 25(OH)vitamin D concentration was not significantly different between 119 ARD [33.4 (IQR 22.5-54.9) nmol/l] and 126 NARD patients 32.9 (IQR 18.7-50.2). In stepwise logistic regression, female sex (F:13.7), winter-spring season (F:5.6) and older age (F:5.3), but not ARD, predicted plasma 25(OH)vitamin D <75 nmol/l. Cholecalciferol supplementation increased 25(OH)vitamin D plasma concentration equally in both ARD and NARD; however, only 29/100 patients reached a plasma level ≥75 nmol/l without differences between ARD and NARD (χ(2) = n.s.). Hypovitaminosis D is common in rheumatic patients. Sex and age but not ARD are risk factors for this condition. 750-1,000 UI/die of cholecalciferol is not sufficient to normalize plasma level in these patients. Increase of plasma 25(OH)vitamin D after treatment is not influenced by the presence of an inflammatory autoimmune disease.


Asunto(s)
Enfermedades Autoinmunes/sangre , Colecalciferol/uso terapéutico , Enfermedades Reumáticas/sangre , Deficiencia de Vitamina D/tratamiento farmacológico , Vitamina D/análogos & derivados , Vitaminas/uso terapéutico , Anciano , Enfermedades Autoinmunes/complicaciones , Enfermedades Autoinmunes/tratamiento farmacológico , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Enfermedades Reumáticas/complicaciones , Enfermedades Reumáticas/tratamiento farmacológico , Resultado del Tratamiento , Vitamina D/sangre , Deficiencia de Vitamina D/sangre , Deficiencia de Vitamina D/complicaciones
12.
Eur J Endocrinol ; 164(5): 833-8, 2011 May.
Artículo en Inglés | MEDLINE | ID: mdl-21310873

RESUMEN

CONTEXT: In healthy subjects and in patients with primary hyperparathyroidism (PH), the administration of a low dose of 25(OH)D (25 µg/day) increases the serum levels of both 25(OH)D and 1,25(OH)(2)D. It is unknown whether this relationship is present in patients affected by familial benign hypocalciuric hypercalcemia (FBH). OBJECTIVE: To evaluate the different vitamin D substrate-product relationship after oral vitamin D supplementation in familial benign hypercalcemia, PH, and healthy controls. DESIGN: We evaluated the main physiological regulators of 1α-hydroxylase and the substrate-product relationship of 25(OH)D and 1,25(OH)(2)D in 20 patients with PH, 25 with FBH, and 122 healthy sex- and age-matched controls before and after administration of 25(OH)D for 2 weeks. RESULTS: 25(OH)D increased significantly in all subjects, whereas 1,25(OH)(2)D serum levels increased significantly in PH patients and healthy controls but not in patients with FBH. Therefore, a significant positive substrate-product relationship of 25(OH)D-1,25(OH)(2)D was found in PH and healthy controls, but not in FBH. Monomeric calcitonin (hCT-M) was significantly lower at baseline and after 25(OH)D supplementation in the FBH group compared with the other two groups. CONCLUSIONS: The lack of 1,25(OH)(2)D increase in FBH may be due to a direct inhibitory effect on 1α-hydroxylase of hypercalcemia per se, increased metabolic clearance of 1,25(OH)(2)D, or a decreased stimulus of 1α-hydroxylase related to persistently low levels of hCT.


Asunto(s)
Hiperparatiroidismo Primario/sangre , Hiperparatiroidismo Primario/tratamiento farmacológico , Vitamina D/administración & dosificación , Vitamina D/sangre , Administración Oral , Anciano , Suplementos Dietéticos , Femenino , Humanos , Hipercalcemia/sangre , Hipercalcemia/congénito , Hipercalcemia/tratamiento farmacológico , Masculino , Persona de Mediana Edad , Especificidad por Sustrato
13.
Parkinsonism Relat Disord ; 15(5): 339-46, 2009 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-19346153

RESUMEN

Patients affected by Parkinson's disease are at a high risk for fractures, mainly of the hip. These fractures are caused by falls due to postural imbalance, neurological impairment and reduced bone mass. The purpose of this study was (1) to investigate the correlations and the pathophysiological mechanisms underlying bone loss in Parkinson's disease and appraise bone loss or fracture risk reduction interventions; (2) to develop a research agenda that informs the design and development of risk reduction strategies. Osteoporosis and osteopenia are very common findings in patients with Parkinson's disease, affecting up to 91% of women and 61% of men. Reduced bone mass in Parkinsonian patients seems to be caused mainly by reduced mobility through a mechanism similar to that observed in other neurological diseases. Endocrine (such as vitamin D deficiency), nutritional and iatrogenic factors also play an important role in bone mass depletion. Female gender, disease duration and severity (Hoehn and Yahr stages III and IV), old age and low body mass index are related to more severe osteoporosis. Vitamin D supplementation and bisphosphonates seem to be effective in reducing the risk of nonvertebral fractures in patients affected by Parkinson's disease. Prevention and evaluation of osteoporosis through bone mass density assessment should be considered in all patients with Parkinson's disease.


Asunto(s)
Osteoporosis/etiología , Enfermedad de Parkinson/fisiopatología , Anciano , Índice de Masa Corporal , Densidad Ósea/efectos de los fármacos , Densidad Ósea/fisiología , Enfermedades Óseas Metabólicas/epidemiología , Enfermedades Óseas Metabólicas/etiología , Femenino , Fracturas Óseas/epidemiología , Fracturas Óseas/prevención & control , Hormona de Crecimiento Humana/sangre , Hormona de Crecimiento Humana/uso terapéutico , Humanos , Masculino , Osteoporosis/epidemiología , Enfermedad de Parkinson/sangre , Enfermedad de Parkinson/tratamiento farmacológico , Caracteres Sexuales , Tirotropina/uso terapéutico , Vitamina D/uso terapéutico
14.
J Rehabil Med ; 40(10): 870-2, 2008 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-19242626

RESUMEN

OBJECTIVE: To explore the effect of treatment after botulinum toxin type A combined with treatments for the spastic foot. DESIGN: Single-blind, randomized trial, with 3-month follow-up. SUBJECTS: Twenty-three chronic hemiplegic adult patients with spastic equinus foot. METHODS: Following botulinum toxin type A injection at the medial and lateral gastrocnemius, patients were assigned randomly to 3 groups, and treated with taping, electrical stimulation or stretching. They were evaluated before treatment (t0), and at 10 (t1), 20 (t2) and 90 (t3) days after treatment. Outcome measures were: Modified Ashworth Scale; passive range of motion at the ankle; measurement of muscle action potential at the gastrocnemius medialis; and measurement of maximum ankle dorsiflexion angle in stance using gait analysis. RESULTS: The group treated with electrical stimulation performed better at t1 on the Modified Ashworth Scale. The taping and electrical stimulation groups performed better in all outcome measures at t3. The taping group performed better mainly for maximum ankle dorsiflexion angle in stance. The stretching group showed a less durable result, with some worsening at the t3 evaluation compared with the assessment performed before treatment. CONCLUSIONS: This pilot study indicates that combining botulinum toxin type A administration for the ankle plantar flexors with taping and electrical stimulation might be beneficial.


Asunto(s)
Toxinas Botulínicas Tipo A/uso terapéutico , Pie/fisiopatología , Trastornos Neurológicos de la Marcha/tratamiento farmacológico , Espasticidad Muscular/tratamiento farmacológico , Fármacos Neuromusculares/uso terapéutico , Adulto , Anciano , Vendajes , Toxinas Botulínicas Tipo A/administración & dosificación , Terapia por Estimulación Eléctrica , Femenino , Estudios de Seguimiento , Trastornos Neurológicos de la Marcha/fisiopatología , Trastornos Neurológicos de la Marcha/terapia , Hemiplejía/etiología , Hemiplejía/fisiopatología , Hemiplejía/rehabilitación , Humanos , Masculino , Persona de Mediana Edad , Espasticidad Muscular/fisiopatología , Espasticidad Muscular/terapia , Ejercicios de Estiramiento Muscular , Fármacos Neuromusculares/administración & dosificación , Proyectos Piloto , Rango del Movimiento Articular , Férulas (Fijadores) , Accidente Cerebrovascular/complicaciones , Accidente Cerebrovascular/fisiopatología , Rehabilitación de Accidente Cerebrovascular , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA